Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

CV Sciences (CVSI) Net Income towards Common Stockholders (2016 - 2025)

CV Sciences' Net Income towards Common Stockholders history spans 14 years, with the latest figure at $379000.0 for Q4 2025.

  • On a quarterly basis, Net Income towards Common Stockholders fell 72.93% to $379000.0 in Q4 2025 year-over-year; TTM through Dec 2025 was -$373000.0, a 39.18% decrease, with the full-year FY2025 number at -$373000.0, up 84.42% from a year prior.
  • Net Income towards Common Stockholders hit $379000.0 in Q4 2025 for CV Sciences, up from -$382000.0 in the prior quarter.
  • Over the last five years, Net Income towards Common Stockholders for CVSI hit a ceiling of $5.7 million in Q1 2023 and a floor of -$8.9 million in Q4 2021.
  • Historically, Net Income towards Common Stockholders has averaged -$1.1 million across 5 years, with a median of -$606000.0 in 2024.
  • Biggest five-year swings in Net Income towards Common Stockholders: tumbled 2477.5% in 2022 and later surged 476.63% in 2023.
  • Tracing CVSI's Net Income towards Common Stockholders over 5 years: stood at -$8.9 million in 2021, then skyrocketed by 73.89% to -$2.3 million in 2022, then skyrocketed by 62.43% to -$869000.0 in 2023, then surged by 261.1% to $1.4 million in 2024, then crashed by 72.93% to $379000.0 in 2025.
  • Business Quant data shows Net Income towards Common Stockholders for CVSI at $379000.0 in Q4 2025, -$382000.0 in Q3 2025, and -$261000.0 in Q2 2025.